NZ731591A - Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone - Google Patents

Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone

Info

Publication number
NZ731591A
NZ731591A NZ731591A NZ73159115A NZ731591A NZ 731591 A NZ731591 A NZ 731591A NZ 731591 A NZ731591 A NZ 731591A NZ 73159115 A NZ73159115 A NZ 73159115A NZ 731591 A NZ731591 A NZ 731591A
Authority
NZ
New Zealand
Prior art keywords
benzoic acid
oxycodone
conjugates
heteroaryl carboxylic
compound
Prior art date
Application number
NZ731591A
Other languages
English (en)
Inventor
Jaroslaw Kanski
Andrea K Martin
Sven Guenther
Bindu Bera
Sanjib Bera
Travis Mickle
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of NZ731591A publication Critical patent/NZ731591A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ731591A 2014-11-25 2015-11-25 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone NZ731591A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084216P 2014-11-25 2014-11-25
US201462084246P 2014-11-25 2014-11-25
PCT/US2015/062637 WO2016086113A1 (en) 2014-11-25 2015-11-25 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone

Publications (1)

Publication Number Publication Date
NZ731591A true NZ731591A (en) 2018-06-29

Family

ID=56075034

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ731591A NZ731591A (en) 2014-11-25 2015-11-25 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone

Country Status (18)

Country Link
US (3) US9850252B2 (enExample)
EP (1) EP3223819A4 (enExample)
JP (2) JP6400848B2 (enExample)
KR (2) KR101976101B1 (enExample)
CN (1) CN106999486A (enExample)
AU (1) AU2015353502B2 (enExample)
BR (1) BR112017011069A2 (enExample)
CA (1) CA2967424C (enExample)
CL (1) CL2017001353A1 (enExample)
CO (1) CO2017005201A2 (enExample)
IL (1) IL252470B (enExample)
MX (1) MX2017006520A (enExample)
NZ (1) NZ731591A (enExample)
PH (1) PH12017500963A1 (enExample)
RU (1) RU2683317C2 (enExample)
SG (1) SG11201704178UA (enExample)
WO (1) WO2016086113A1 (enExample)
ZA (1) ZA201703154B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
SG11201704178UA (en) 2014-11-25 2017-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
US20200038383A1 (en) * 2016-10-14 2020-02-06 Kempharm, Inc. Immediate-release abuse deterrent compositions or medicaments for treating pain, add, adhd and other syndromes or disorders
WO2019018638A1 (en) 2017-07-20 2019-01-24 Suzhou Runxindatai Pharmaceutics Ltd Co. PRODRUGS OF EXTENDED RELEASE OPIOID OPIOIDS RESISTANT TO ABUSE
AU2019224127B2 (en) * 2018-02-23 2021-12-09 Rhodes Technologies Novel opioid compounds and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB320749A (enExample)
US1731152A (en) 1925-10-27 1929-10-08 Firm C H Boehringer Sohn Process for the manufacture of derivatives of dihydrocodeinone or its substitution products
AT229496B (de) 1961-03-08 1963-09-25 Lannacher Heilmittel Verfahren zur Darstellung des neuen Nicotinsäureesters des Dihydrohydroxycodeinons
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
SE9003665D0 (sv) 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
GB9423542D0 (en) 1994-11-22 1995-01-11 Marples Brian A Pharmaceutical compounds
US5869669A (en) * 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
JP2004501067A (ja) 2000-01-28 2004-01-15 ローム　アンド　ハース　カンパニー 高められた特性をもつ医薬
WO2005032474A2 (en) 2003-09-30 2005-04-14 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
IL158882A0 (en) 2001-06-05 2004-05-12 Control Delivery Sys Inc Sustained-release analgesic compounds
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
AU2003219863C1 (en) 2002-02-22 2009-03-05 Shire Llc Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US20040058946A1 (en) 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
TW200500067A (en) 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
MXPA05009757A (es) * 2003-03-13 2005-12-05 Controlled Chemicals Inc Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida.
EP1782834A3 (en) * 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
CA2541371C (en) 2003-10-03 2014-12-16 Atul M. Mehta Extended release formulations of opioids and method of use thereof
US20050203115A1 (en) * 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
US7342131B2 (en) 2004-06-04 2008-03-11 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US7348430B2 (en) 2005-01-21 2008-03-25 Acura Pharmaceuticals, Inc. Production of opioid analgesics
EP2007762A2 (en) * 2006-04-10 2008-12-31 Shire LLC Mono and di-substituted oxycodone compounds and compositions
JP5371746B2 (ja) 2006-05-26 2013-12-18 ファーマコフォア， インコーポレイテッド フェノール性オピオイドの制御放出
US20080090771A1 (en) 2006-10-06 2008-04-17 Shire Llc Abuse-resistant hydrocodone compounds, compositions and methods of using the same
NZ586194A (en) 2007-12-17 2012-07-27 Mallinckrodt Llc Processes for the production of (+)-'nal' morphinan compounds
UA102916C2 (uk) * 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
CA2765836C (en) 2009-07-02 2014-10-07 Kempharm, Inc. Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, methods of making and use thereof
WO2011008636A1 (en) 2009-07-15 2011-01-20 Mallinckrodt Inc. 3-oxy-hydromorphone derivatives
WO2012096887A2 (en) * 2011-01-11 2012-07-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
HK1197191A1 (en) * 2011-10-26 2015-01-09 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
SG11201704178UA (en) 2014-11-25 2017-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone

Also Published As

Publication number Publication date
KR20190049944A (ko) 2019-05-09
AU2015353502A1 (en) 2017-05-25
KR20170094249A (ko) 2017-08-17
RU2017122144A3 (enExample) 2018-12-26
US10544153B2 (en) 2020-01-28
US9850252B2 (en) 2017-12-26
US10144740B2 (en) 2018-12-04
CO2017005201A2 (es) 2017-08-31
RU2683317C2 (ru) 2019-03-28
CL2017001353A1 (es) 2018-01-05
PH12017500963A1 (en) 2017-10-18
JP2018199719A (ja) 2018-12-20
JP2017535593A (ja) 2017-11-30
US20160168160A1 (en) 2016-06-16
CA2967424A1 (en) 2016-06-02
ZA201703154B (en) 2019-03-27
US20180065975A1 (en) 2018-03-08
KR101976101B1 (ko) 2019-05-09
CN106999486A (zh) 2017-08-01
RU2017122144A (ru) 2018-12-26
WO2016086113A1 (en) 2016-06-02
JP6400848B2 (ja) 2018-10-03
EP3223819A1 (en) 2017-10-04
US20190048018A1 (en) 2019-02-14
IL252470A0 (en) 2017-07-31
CA2967424C (en) 2023-05-02
IL252470B (en) 2019-08-29
BR112017011069A2 (pt) 2018-07-10
AU2015353502B2 (en) 2018-09-27
EP3223819A4 (en) 2018-04-25
SG11201704178UA (en) 2017-06-29
MX2017006520A (es) 2017-08-09

Similar Documents

Publication Publication Date Title
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
WO2013188783A8 (en) Deuterated derivatives of ruxolitinib
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
WO2015095811A8 (en) Combination therapy with neoantigen vaccine
HK1244708A1 (zh) 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法
PH12018500061A1 (en) Oxysterols and methods of use thereof
HK1255500A1 (zh) 氧固醇及其使用方法
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
NZ704266A (en) Inhibitors of alpha-crystallin aggregation for the treatment for cataract
EP3412668A3 (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
WO2013106761A3 (en) Antimicrobial agents
HK1220136A1 (zh) 治疗b2-缓激肽受体介导的血管性水肿的方法
PH12016500666A1 (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
WO2014201016A3 (en) Inhibitors of the mitf molecular pathway
UA109793C2 (uk) Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс)
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
MX2015008292A (es) Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
JO2820B1 (en) Combination of refined thiazolium salt or a primary compound and artemisinin or a derivative thereof to treat serious malaria cases
NZ707832A (en) 2-pyridone compound
MX360889B (es) Forma cristalina de un compuesto usado como un antagonista del receptor mineralocorticoide y metodo de preparacion de la misma.
WO2017085733A3 (en) Analgesic lipoic acid derivatives and the preparation thereof
WO2014060942A3 (en) Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
CR20200565A (es) Coposiciones antimicrobianas con agentes efervescentes (divisional exp. 2016-0592)

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed